Scottish Medicines Consortium
Providing advice about the status of all newly licensed medicines
www.scottishmedicines.org.uk
Delta House 50 West Nile Street Glasgow G1 2NP Tel 0141 225 6999 Chairman: Professor Jonathan G Fox

Product Update:

diamorphine hydrochloride 720 microgram/actuation and 1600 microgram/actuation nasal spray (Ayendi®) SMC No. (1172/16)
Wockhardt UK Ltd

08 July 2016

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

diamorphine hydrochloride (Ayendi®) is accepted for use within NHS Scotland.

Indication under review: treatment of acute severe nociceptive pain in children and adolescents in a hospital setting. Diamorphine hydrochloride nasal spray (Ayendi®) should be administered in the emergency setting by practitioners experienced in the administration of opioids in children and with appropriate monitoring.

Unlicensed intranasal diamorphine has been used in the NHS in Scotland for the treatment of severe pain in children in the emergency setting. The availability of diamorphine hydrochloride nasal spray (Ayendi®) provides a licensed preparation.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 3 June 2016.

Chairman,
Scottish Medicines Consortium

Published 08 August 2016